Erectile dysfunction is one of the most common sexual health disorders, and it affects a significant portion of the male population. The high prevalence of ED and associated chronic conditions such as prostate cancer, benign prostate hyperplasia, diabetes, CVDs, which can, in turn, pose as a high-risk factor for the occurrence of this disease are factors driving the development of innovative drug and device therapy in the global market. Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable healthcare guidelines will enable vendors to launch new treatment solutions in the global erectile dysfunction market. The recent emergent low-intensity extra-corporeal shockwave therapy holds the potential to deliver a permanent treatment solution to the disease during the forecast period.

The global erectile dysfunction market is estimated to generate revenues of over $4.5 billion by 2023.

The various device therapy available in the erectile dysfunction market are:

·         Penile Implants

Penile implants are known as a penile prosthesis. These implants are the medical devices that are implanted into the penis through an outpatient surgical procedure. Penile implants were one of the initial therapies to be used for the treatment of erectile dysfunction. Penile implants are considered as an end-stage treatment option for ED.

Two broad types of penile implants are currently available in the market, and it consists of non-inflatable implants (3-piece and 2-piece) and non-inflatable or malleable implants. The leading vendors are focusing on introducing advances in penile prosthesis to make the implant more natural, durable, and reliable devices. The various prosthesis available in the market includes kink resistant tubing, rear tip extenders, lock-out valve, tactile pump, polypropylene cylinder coating, and antibiotic-impregnated devices. The key benefits of penile implants include potential to cure the disease permanently, end-therapy for an option for other therapy type non-responders, high patient satisfaction rates, and leads to a more natural erection. The key players are investing in the R&D for innovative, superior, and newer generation prosthesis with safer and high-efficacy profile as the demand for better quality products is the top priority for healthcare providers as well as patients.

·         Vacuum Therapy Devices

Vacuum therapy devices use negative pressure to distend the corporal sinusoids and increase the blood inflow to the penis, thereby achieving penile erections. The device consists of a hollow tube, automated or manual pump, and constriction rings. Vacuum therapy devices may be classified as vacuum constriction device (VCD) and vacuum erectile device (VED). The VCD features an external constricting ring, which needs to be placed at the base of the penis to prevent blood outflow from the corpora cavernosa to maintain an erection. The VED uses the vacuum therapy without a constrictive ring, with the objective of increasing blood oxygenation in the corpora cavernosa. The use of VCDs are considered as one of a key non-invasive, effective, safe, drug-free and cost-effective erectile dysfunction treatment options, especially for PDE5 non-responders, and these devices are often used in penile rehabilitation programs. The increasing commercial availability of these vacuum therapy devices will boost the adoption of these devices and result in effective management of erectile dysfunction in the global market. The increase in a number of people seeking erectile dysfunction treatment, growth in e-commerce promotions and marketing of VCDs, and increase in disease awareness, high availability of OTC certified devices will propel the growth of the market during the forecast period.

·         Others Erectile Dysfunction Devices

The discoveries and technological innovations through medical research is resulting in the expansion of treatment modalities for various diseases, especially erectile dysfunction. The top players are leveraging technology to introduce a wide range option in the global market such as external penile support devices, penile vibrators, and low-intensity extracorporeal shockwave devices. The use of low-intensity extracorporeal shockwave (LI-ESW) for the treatment of ED is one of highly research areas. The device is a new and noninvasive technique to modify the structures involved in developing an erection through the application of shockwaves to targeted sites along the penile shaft, which, in turn, causes reactions that result in neovascularization of the penile tissue. The product is approved for use in select countries such as Saudi Arabia, Brazil, Indonesia, Colombia, and Mexico.

The prominent players operating in the erectile dysfunction market are Bayer AG, Eli Lilly and Company, VIVUS, Inc, Pfizer, Boston Scientific Corp., and Coloplast A/S.

View Arizton's Full Report On Global Erectile Dysfunction MarketView Arizton's Full Report On Global Premature Ejaculation Market

You may reach us at

enquiry@arizton.com